An Advanced Formulation of a Magnesium Dietary Supplement Adapted for a Long-Term Use Supplementation Improves Magnesium Bioavailability: In Vitro and Clinical Comparative Studies.
Study Goal
The researchers aimed to compare the magnesium release profile and bioavailability of a low-dose continuous-release magnesium chloride tablet (ChronoMag®) with a reference tablet at a standard dose (300 mg).
Results Summary
The low-dose formulation provided continuous magnesium release for 6 hours, compared to the reference tablet's complete release within 1 hour. Cumulative urinary magnesium levels were 76-89% of the reference tablet's levels, suggesting improved absorption and bioavailability.
Population
12 normo-magnesemic healthy volunteers
Effective Dosage
100 mg magnesium element (two 50 mg tablets once daily) for ChronoMag®; 300 mg magnesium element (three 100 mg tablets) for the reference tablet
Duration
Not specified in the abstract
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
ChronoMag® (low-dose continuous-release magnesium chloride tablet) | decrease | gastrointestinal side effects | - | decreasing the risk | was designed to provide | #1 |
ChronoMag® (low-dose continuous-release magnesium chloride tablet) | increase | long-term supplementation | health conditions related to low magnesium levels | - | allowing | #2 |
reference tablet (300 mg magnesium element) | decrease | magnesium | - | 100% within 1 h | released | #3 |
magnesium chloride formulation (ChronoMag®) | increase | magnesium | - | continuous for 6 h | release was | #4 |
ChronoMag® (patented magnesium chloride tablets) | increase | urinary magnesium levels | 12 normo-magnesemic healthy volunteers | 76% (0-5 h) | cumulative urinary magnesium levels compared to those with the reference tablet were | #5 |
ChronoMag® (patented magnesium chloride tablets) | increase | urinary magnesium levels | 12 normo-magnesemic healthy volunteers | 89% (0-10 h) | cumulative urinary magnesium levels compared to those with the reference tablet were | #6 |
ChronoMag® (patented magnesium chloride tablets) | increase | urinary magnesium levels | 12 normo-magnesemic healthy volunteers | 87% (0-24 h) | cumulative urinary magnesium levels compared to those with the reference tablet were | #7 |
both supplements | no change | elimination | - | fairly similar | elimination after 24 h was | #8 |
new magnesium chloride formulation (ChronoMag®) | increase | absorption and bioavailability | - | - | improves | #9 |
new magnesium chloride formulation (ChronoMag®) | increase | high absorption | - | - | allowing | #10 |
new magnesium chloride formulation (ChronoMag®) | increase | gastrointestinal tolerance | long-term use | - | may improve | #11 |
While general recommendations are for 300-mg magnesium intake a day, an advanced low-dose formulation of magnesium chloride, ChronoMag®, was designed to provide 100 mg of magnesium element, thus decreasing the risk of gastrointestinal side effects and allowing long-term supplementation in health conditions related to low magnesium levels. The present study aimed to compare magnesium release profile and bioavailability between this patented low-dose continuous-release magnesium chloride tablet (100 mg magnesium element) and a reference tablet at the usually prescribed dose (300 mg magnesium element). Magnesium release profile was determined by dissolving the tablets in solutions simulating the gastrointestinal tract environment. A randomized double-blind crossover controlled trial of ChronoMag® versus reference tablet (3 × 100 mg magnesium element tablets) in 12 normo-magnesemic healthy volunteers was conducted to evaluate the bioavailability of the patented magnesium chloride tablets (two 50 mg magnesium tablets, once-a-day intake). While the reference tablet released 100% of its magnesium within 1 h of dissolution, release from the magnesium chloride formulation was continuous for 6 h. Cumulative urinary magnesium levels compared to those with the reference tablet were 76% (0-5 h), 89% (0-10 h), and 87% (0-24 h). Elimination after 24 h was fairly similar with both supplements. Our results suggest that the new magnesium chloride formulation, providing continuous low-dose magnesium release throughout the gastrointestinal tract, improves absorption and bioavailability. This formulation conforms to the physiological mechanism of magnesium absorption throughout the digestive tract, allowing high absorption, and may improve gastrointestinal tolerance in long-term use.